Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.

Importantly, in this nonrandomized real-life cohort with selection criteria described above, the frequency of prior grade 2–4 aGVHD was similar to the earlier BMTCTN 0201 cohort in PB transplant at approximately 45%, with a slight trend toward less prior aGVHD in the BM group.

also in 4,078 other papers

Of note, aGVHD grade 2–4 before day 90 for PB and BM did not reach statistical significance.

also in 111,027 other papers